Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making-Reference-Cited by-同舟云学术

Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making

Published:2021-04 Issue:4 Volume:24 Page:505-512
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Tai Ting-An,Latimer Nicholas R.,Benedict Ágnes,Kiss Zsofia,Nikolaou Andreas

Funder

Yorkshire Cancer Research

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference36 articles.

1. Methods for the Economic Evaluation of Health Care Programmes;Drummond,2015

2. Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable?;Paulden;Expert Rev Pharmacoecon Outcomes Res,2017

3. Decision Modelling for Health Economic Evaluation;Briggs,2006

4. Accelerated approval of oncology products: a decade of experience;Dagher;J Natl Cancer Inst,2004

5. Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide;Latimer;Med Decis Making,2013

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden;Medical Decision Making;2024-09-12

2. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06

3. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia;PharmacoEconomics;2024-01-06

4. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States;Journal of Medical Economics;2023-12-19

5. An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund;PharmacoEconomics - Open;2023-12-12